Provider of integrated genomic analysis platform. The company uses its core algorithm as a core technology for analyzing exhaustive epigenome data obtained from the next-generation sequencer. The company also provides next-generation sequencing data analysis services. Founded in 2015, headquartered in Chiyoda City, Japan. The company has raised $5.6M in funding at the series b stage. The team comprises 8 (Jun 30, 2026) employees. The company operates in the Genomics sector with additional focus on Life Sciences Tech and Life Sciences Tech. Its business model centers on Omics Analysis. Founded in 2015, headquartered in Chiyoda City, Japan. The company has raised $5.6M at the Series B stage. Backed by investors including Leave a Nest Capital, JFC, Joyo Bank, Daiwa Corporate Investment, Kirin and others.
Rhelixa
Series BProvider of integrated genomic analysis platform. The company uses its core algorithm as a core technology for analyzing exhaustive epigenome data obtained from the next-generation sequencer. The company also provides next-generation sequencing data analysis services. Founded in 2015, headquartered in Chiyoda City, Japan. The company has raised $5.6M in funding at the series b stage. The team comprises 8 (Jun 30,…
About
Business model
Life Sciences Tech > Research & Development > Drug Informatics > Clinical Data Analysis > Omics Analysis,
Genomics > Genome Informatics > Integrative Bioinformatics Platforms
Institutional investors
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.